Results 61 to 70 of about 3,083,119 (212)
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy +11 more
wiley +1 more source
Pasifika Healthcare Workers' Perspectives of Psychedelic-Assisted Therapy
Recent studies indicate that psychedelic-assisted therapy may assist with various psychological issues, including depression, anxiety, and existential distress.
Nuha, Musheerah
core
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove +3 more
wiley +1 more source
Simulating Psychedelic Therapy Through Mediated Reality
Due to the illegality of psychedelic substances, and despite proven efficiency, people suffering from various psychiatric illnesses and disorders are unable to receive potentially life-changing psychedelic therapy.
Hillstead, Andrew (11745590) +2 more
core +1 more source
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve +6 more
wiley +1 more source
Creating Greater Safety in Psychedelic-Assisted Therapy Spaces
As the medical legalization of psychedelic-assisted therapy quickly approaches in Western society, more stories of abuse by psychedelic therapists against clients are emerging, tracing a disturbing pattern and history of exploitation and abuses of power ...
Maira Evelyn Clancy
core
Psychedelic-assisted therapy research for depression and PTSD has been fast tracked in the United States with the Food and Drugs Administration (FDA) granting breakthrough designations for MDMA (post-traumatic stress disorder) and psilocybin (major ...
Henry J. Whitfield (11803265)
core +1 more source
Abstract Aims ‘Mad honey’ is produced when bees collect nectar from Rhododendron species containing grayanotoxins, naturally occurring diterpenoid toxins that can produce dose‐dependent intoxication. It has long been embedded in Nepalese medicinal and ritual practices but has recently become part of global psychedelic discourse. This study examined how
Sharon R. Sznitman, Surendra Tiwari
wiley +1 more source
Insurance Coverage for Psychedelic Therapy
As psychedelic-assisted therapies advance through the FDA approval pipeline, the question of who will pay for them is moving from academic to urgent. Experts project that MDMA-assisted therapy for PTSD will cost upwards of $11,000-$12,000 per course of ...
Vincent Joralemon
core +1 more source
Abstract Aims To characterize changes in preferred e‐cigarette (EC) flavor, nicotine concentration, wattage and air valve openness over 12 weeks among adults who smoke and are attempting to switch to ECs, and examine whether these changes are associated with cigarettes smoked per day (CPD).
Yoo Jin Cho +11 more
wiley +1 more source

